How Trump's psychedelics executive order could unlock stalled cannabis reform
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and iboga...
Last updated: 2026-04-20 19:30:42 ET
Pulse AI Brief
Updated Apr 20, 2026 7:00 PM ET
Psychedelic-focused biotech stocks rallied after President Trump signed an executive order aimed at expediting FDA review timelines for psychedelic-based treatments for mental illness. The regulatory acceleration removes a key bottleneck for clinical programs in psilocybin and MDMA-
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and iboga... 'lead a happier life' President Trump signed an executive order Saturday that eases restrictions on the research of the psychedelics including the drug ibogaine, which is u... Ibogaine is banned under the federal government's most restrictive category for illegal, high-risk drugs. The president will direct federal agencies to boost research into the drugs and support clinical trials, moves championed by Robert F. Kennedy Jr.Mentions (24h)
Mentions (Range)
Sentiment (Avg / Median)
Sentiment Mix (Range)
Coverage Z-Score
Latest Articles on "psychedelics" (Range)
How Trump's psychedelics executive order could unlock stalled cannabis reform
Trump Signs Executive Order Speeding Up Research On Using Psychedelics For Mental Health
Watch: Trump signs executive order easing U.S. restrictions on psychedelic research
Trump signs order to speed review of psychedelics, including the controversial drug ibogaine
Trump plans to ease access to psychedelics like psilocybin, ibogaine
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE